Last reviewed · How we verify
Collection of biological samples
Collection of biological samples is a Biologic drug developed by University Hospital, Toulouse. It is currently in Phase 3 development.
This is a biospecimen collection protocol, not a drug with a pharmacological mechanism of action.
At a glance
| Generic name | Collection of biological samples |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
A 'Collection of biological samples' is a research procedure or protocol used to gather biological specimens (blood, tissue, etc.) from study participants, typically for diagnostic, prognostic, or research purposes in clinical trials. It is not a therapeutic agent and does not have a molecular mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Collection of biological samples CI brief — competitive landscape report
- Collection of biological samples updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI